Envirotech Vehicles appoints Jason Maddox to board of directors
In a recent transaction, Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), sold 11,855 shares of common stock. The company, currently valued at $246 million, has received a "GOOD" financial health rating from InvestingPro analysts. The shares were sold at a weighted average price of approximately $3.47, resulting in a total transaction value of $41,103. This sale was executed on February 3, 2025, and was required to cover tax withholding obligations related to the vesting of restricted stock units. The stock, currently trading at $3.69, has moved significantly from its 52-week range of $1.57 to $19.95, and appears undervalued according to InvestingPro’s Fair Value analysis. Following this transaction, Klee holds 3,164,933 shares directly. The sales were automatic and not at Klee’s discretion, according to the filing. For deeper insights into AMLX’s valuation metrics and exclusive ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Amylyx Pharmaceuticals has been cleared by the FDA to resume the Phase 1 trial for AMX0114, a potential treatment for amyotrophic lateral sclerosis (ALS). The trial, known as LUMINA, will involve approximately 48 individuals with ALS. The company also announced a collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist for diabetes treatment.
Amylyx received differing ratings from analysts. H.C. Wainwright maintained a positive outlook, reiterating a Buy rating. The rating follows Amylyx’s recent disclosure of their Phase 3 trial design for avexitide, a treatment for post-bariatric hypoglycemia (PBH). Goldman Sachs, however, maintained a Neutral rating on Amylyx, citing uncertainties in the PBH market.
Baird analyst Joel Beatty revised the rating for Amylyx, raising it from Neutral to Outperform, with a significant increase in the price target, now set at $11.00. The upgrade reflects growing optimism about the company’s prospects, particularly concerning avexitide. These developments are part of the company’s recent strategic moves and product pipeline expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.